# ADAURA (NCT02511106)

> AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02511106
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Stage IB-IIIA Non-small Cell Lung Carcinoma
- Interventions: AZD9291 80 mg/40 mg; Placebo AZD9291 80 mg/40 mg; Open-label AZD9291 80 mg/40 mg
- Enrollment: 682
- Primary outcome: Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS).

## Commentary we found

- X threads: 566
- Podcasts: 107
- YouTube: 100
- X videos: 11

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=adaura-nct02511106

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02511106", "email": "<work email>"}; the inbox owner confirms by the emailed link.